Intuitive Surgical’s ISRG Ion platform is increasingly emerging as a potentially meaningful growth engine, supported by accelerating procedural adoption and growing clinical validation in lung cancer care.
In the first quarter of 2026, Ion procedures grew 39% year over year to 43,000, substantially outpacing overall company procedure growth and reinforcing management’s conviction that the platform can play a larger role in pulmonary diagnostics and intervention. Management reiterated that Ion’s key achievement is improving lung cancer patient survival, positioning the platform as more than just an incremental robotic product.
Clinical evidence is strengthening the case. A recently published Mayo Clinic study, evaluating approximately 2,000 patients, demonstrated that Ion-supported robotic bronchoscopy achieved a 79% diagnostic yield under strict ATS/ACCP consensus definitions and an 85% sensitivity in detecting malignancy.
The study demonstrated a significant shift toward earlier-stage diagnosis, with the proportion of primary lung cancers detected at an early stage increasing from 46% in 2019 to 69% in 2024. Because earlier detection is closely linked to better survival outcomes, the findings highlight Ion’s potential to meaningfully improve the lung cancer treatment pathway.
Intuitive Surgical is also pursuing an integration roadmap aimed at streamlining diagnosis and staging. Management is progressing well with its rapid on-site tissue evaluation (ROSE) and endobronchial ultrasound (EBUS) integration. These technologies could allow physicians to move from detection to diagnosis and lymph node staging during a single anesthetic event. The Mayo study showed that 74% of patients underwent concurrent EBUS staging, highlighting the clinical value of an integrated workflow.
Ion could materially expand Intuitive Surgical’s total addressable market (TAM) over the long term in the lucrative lung cancer market. By improving access to minimally invasive biopsy, accelerating diagnosis and potentially improving survival, the platform may extend beyond diagnostics into broader lung disease management and intervention. While still early-stage, Ion is increasingly being positioned as a foundational platform in the future of lung cancer care.
Peer Updates
Globus Medical’s GMED long-term growth strategy is centered on building an integrated musculoskeletal ecosystem combining robotics, enabling technologies, implants and surgical intelligence to deepen market share and improve procedural outcomes.
Management highlighted ExcelsiusGPS robotics pull-through, competitive sales recruiting, and cross-selling as key growth drivers, while shifting toward flexible leasing models to accelerate robot placements and recurring implant revenue. The recent FDA clearance of patient-specific spinal spacers and rods, integrated with the Excelsius platform, further enhances differentiation and positions Globus Medical as a one-stop shop for personalized spine surgery. Its closed-loop surgical intelligence platform, robotics capabilities, and vertically integrated manufacturing could support durable growth and margin expansion
Stereotaxis STXS is focused on transforming itself into a broader robotic endovascular surgery platform, with long-term growth increasingly tied to recurring catheter revenues and next-generation robotic systems. Key growth drivers include the rollout of the MAGiC ablation catheter, which reduces reliance on third parties while generating high recurring revenue per procedure, and GenesisX, a more flexible robotic system that can be installed without cath lab reconstruction.
The newly approved Synchrony digital surgery cockpit, along with planned AI-driven decision support, automation and remote capabilities, could further expand adoption. Management sees robotics, AI and interoperability as the foundation for treating cardiovascular disease and stroke at scale.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 22.6% so far this year compared with an 17.5% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 40.12, above the industry average. But, it is still lower than its five-year median of 70.07. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 16.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Stereotaxis Inc. (STXS): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).